EP 1121345 A1 20010808 - ESTERS OF (+)-ALPHA-( 2,3- DIMETHOXYPHENYL) -1- 2-(4- FLUOROPHENYL) ETHYL -4- PIPERIDINEMETHANOL AND THEIR USE AS PRODRUGS OF THE 5HT2A RECEPTOR ANTAGONIST MDL 110,907
Title (en)
ESTERS OF (+)-ALPHA-( 2,3- DIMETHOXYPHENYL) -1- 2-(4- FLUOROPHENYL) ETHYL -4- PIPERIDINEMETHANOL AND THEIR USE AS PRODRUGS OF THE 5HT2A RECEPTOR ANTAGONIST MDL 110,907
Title (de)
ESTER DES (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-¬2-(4-FLUORPHENYL)ETHYL -4-PIPERIDINMETHANOLS UND IHRE ANWENDUNG ALS MEDIKAMENTVORSTUFEN DES 5HT2A REZEPTOR-ANTAGONISTEN MDL 110,907
Title (fr)
ESTERS DE (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1- 2-(4-FLUOROPHENYL)ETHYL -4-PIPERIDINEMETHANOL ET LEUR UTILISATION COMME PROMEDICAMENT DE L'ANTAGONISTE DU RECEPTEUR 5HT2A MDL 110,907
Publication
Application
Priority
US 9821608 W 19981014
Abstract (en)
[origin: WO0021930A1] The present invention is directed to esters of (+)- alpha -(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol, of formula (I) wherein R is C4-C20alkyl, pharmaceutical formulations, methods of making and methods of using these esters. These compounds antagonize the effects of serotonin at the 5HT2A receptor and are useful in treating various conditions such as, for example, psychoses such as schizophrenia.
IPC 1-7
IPC 8 full level
C07D 211/48 (2006.01); A61K 31/445 (2006.01); A61P 7/02 (2006.01); A61P 9/06 (2006.01); A61P 9/10 (2006.01); A61P 25/00 (2006.01); A61P 25/18 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 25/30 (2006.01); C07D 211/22 (2006.01)
IPC 8 main group level
CPC (source: EP KR)
A61K 31/445 (2013.01 - KR); A61P 7/02 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/06 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/18 (2017.12 - EP); A61P 25/22 (2017.12 - EP); A61P 25/24 (2017.12 - EP); A61P 25/30 (2017.12 - EP); C07D 211/22 (2013.01 - EP KR)
Citation (search report)
See references of WO 0021930A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE
DOCDB simple family (publication)
WO 0021930 A1 20000420; AU 1083099 A 20000501; BR 9816049 A 20010703; CA 2347469 A1 20000420; CA 2347469 C 20060228; CN 1160333 C 20040804; CN 1314887 A 20010926; CZ 20011331 A3 20010815; EA 003667 B1 20030828; EA 200100361 A1 20011022; EE 200100219 A 20020815; EP 1121345 A1 20010808; HK 1039332 A1 20020419; HR P20010278 A2 20020630; HU P0200517 A2 20020629; HU P0200517 A3 20021228; IL 142479 A0 20020310; IL 142479 A 20060611; JP 2002527422 A 20020827; KR 100515429 B1 20050920; KR 20010106517 A 20011129; NO 20011805 D0 20010409; NO 20011805 L 20010608; NO 320417 B1 20051205; NZ 510631 A 20030725; PL 193306 B1 20070131; PL 347318 A1 20020325; SK 5082001 A3 20011106; TR 200101047 T2 20010821; UA 57859 C2 20030715
DOCDB simple family (application)
US 9821608 W 19981014; AU 1083099 A 19981014; BR 9816049 A 19981014; CA 2347469 A 19981014; CN 98814274 A 19981014; CZ 20011331 A 19981014; EA 200100361 A 19981014; EE P200100219 A 19981014; EP 98953458 A 19981014; HK 02100869 A 20020205; HR P20010278 A 20010412; HU P0200517 A 19981014; IL 14247901 A 20010405; IL 14247998 A 19981014; JP 2000575839 A 19981014; KR 20017004703 A 20010413; NO 20011805 A 20010409; NZ 51063198 A 19981014; PL 34731898 A 19981014; SK 5082001 A 19981014; TR 200101047 T 19981014; UA 01042522 A 19981014